CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 7, 2008
Result type: Reports
Project Number: SR0134-000
Product Line: Reimbursement Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Therapeutic Area: Thromboembolism (venous), prevention

Indications: Thromboembolism (venous), prevention

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 17, 2008

Recommendation Type: List with clinical criteria and/or conditions